We appreciate the interest by Dr. Rassi in our recent study on the role of angiotensin-converting enzyme (ACE) inhibitors and angiotensin receptor blockers (ARBs) in diabetes prevention (1). We agree that lifestyle modifications that increase physical activity and minimize abdominal obesity are the most rational and costeffective strategies for preventing type 2 diabetes. Despite this knowledge, compliance with a prescription for daily exercise and lasting weight loss proves difficult for many people; the epidemic of diabetes continues to escalate. Thus, safe pharmacologic approaches for preventing this disease will probably be relevant and important for many individuals. Screening for new-onset diabetes using the American Diabetes Association criteria of a fasting plasma glucose of Ն126 mg/dl at two different visits in patients with no diabetes at the time of enrollment is a valid initial test to identify this disease at its early stages and prevent its chronic sequelae. However, the use of data from relatively short-term studies to calculate a number-neededto-treat (NNT) can be misleading, as the risk of diabetes accrues over decades or, indeed, a lifetime.
Long-Term Bosentan Treatment in Children With Pulmonary Arterial Hypertension
One of the core principles of scientific research is to provide full details of the experimental methods for replication in further study or clinical practice. As with many published studies (1), Rosenzweig et al. (2) failed to provide details of the drug formulation in their report. Bosentan is currently only commercially available in tablet form, and the dosing used in their study appears to be multiples of halved/quartered tablets. It is widely recognized that splitting tablets causes significant dosing inaccuracy, even when commercially available tablet cutters are used (3, 4) . Furthermore, many children are unable to swallow whole tablets (5) , and crushing the tablets can impair drug absorption (6). Rosenzweig et al. (2) do not report how their patients took the dose (whether or not it was swallowed whole).
If the published report does not detail the drug formulation and method of administration, the reliability of any findings is questionable as the methods cannot be repeated accurately. If tablets were cut in half/quartered and crushed, both the amount of drug administered and its absorption are questionable, bringing the validity of the results into doubt.
In their report, Rosenzweig et al. (2) cite a pharmacokinetic study (7) on the dosing of bosentan in pediatric patients that also fails to give formulation and administration details and whose lowest dose is 31.25 mg as opposed to 15.6 mg in Rosenzweig et al. (2) . Bosentan may well be a useful agent in the treatment of pulmonary arterial hypertension in children; surely it is now time that a pediatric liquid formulation be developed, the efficacy and dose optimization of which can be addressed in a well-conducted prospective clinical trial. 
REPLY
We agree with Dr. Standing that a pediatric formulation of bosentan is needed. The pharmaceutical development of a pediatric formulation, in the form of an orodispersible tablet with a flexible dosage of 8 to 32 mg, is currently undergoing clinical evaluation in children in Europe and in the U.S.
However, during the course of development and validation of the pediatric formulation, the current adult formulation of bosentan was used to begin evaluation of the pharmacokinetics and safety of bosentan in children (1) . We acknowledge that we do not describe in detail in our study (2) the technical aspects associated with cutting the adult tablets for the treatment of children. However, several studies have shown the adult formulation is suitable to this situation:
1. The active bosentan substance is uniformly spread throughout the bosentan tablet. 2. Seventy-five percent of the tablet weight is drug substance, thereby limiting the possibility of nonuniformity of the medication dose. 3. The weight of halved tablets, split with a commercially available tablet cutter, was within European and U.S. Pharmacopeia specifications (Actelion, personal communication, 2001). In addition, dissolution rates were measured and found to be similar for both whole and halved tablets.
Therefore, the use of split tablets was considered appropriate for conducting a pharmacokinetic study (1) . Quartered tablets were not tested at that time. In our study (2), we followed the sponsor's recommendations of using a commercially available cutter to split the tablets, with no crushing of halved/quartered tablets, and direct oral administration.
Whereas the pharmaceutical development of the pediatric formulation of bosentan was ongoing, we treated children with symptomatic pulmonary arterial hypertension (PAH) at our clinics with the adult bosentan formulation following the sponsor's recommendation for dosing in children at that time (i.e., based on a conservative extrapolation by weight of the recommended adult dosages). Using this approach, these data demonstrated the safety and efficacy of bosentan for pediatric PAH. However, we also agree with Dr. Standing that pediatric dosing needs to be studied further. We anticipate that the current evaluation of a pediatric bosentan formulation will lead to optimal bosentan dosing regimens for children with PAH.
